Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 271

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial

Open access
Mellinghoff, Ingo K., Penas-Prado, Marta, Peters, Katherine B., Burris, Howard A., Maher, Elizabeth A., Janku, Filip, Cote, Gregory M., de la Fuente, Macarena I., Clarke, Jennifer L., Ellingson, Benjamin M., Chun, Saewon, Young, Robert J., Liu, Hua, Choe, Sung, Lu, Min, Le, Kha, Hassan, Islam, Steelman, Lori, Pandya, Shuchi S., Cloughesy, Timothy F., Wen, Patrick Y. · 2021 · Clinical Cancer Research

Abstract

Purpose: Lower grade gliomas (LGGs) are malignant brain tumors. Current therapy is associated with short- and long-term toxicity. Progression to higher tumor grade is associated with contrast enhancement on MRI. The majority of LGGs harbor mutations in the genes encoding isocitrate dehydrogenase 1 or 2 (IDH1/IDH2). Vorasidenib (AG-881) is a first-in-class, brain-penetrant, dual inhibitor of the mutant IDH1 and mutant IDH2 enzymes. Patients and Methods: We conducted a multicenter, open-label, phase I, dose-escalation study of vorasidenib in 93 patients with mutant IDH1/2 (mIDH1/2) solid tumors, including 52 patients with glioma that had recurred or progressed following standard therapy. Vorasidenib was administered orally, once daily, in 28-day cycles until progression or unacceptable toxicity. Enrollment is complete; this trial is registered with ClinicalTrials.gov, NCT02481154. Results: Vorasidenib showed a favorable safety profile in the glioma cohort. Dose-limiting toxicities of elevated transaminases occurred at doses ≥100 mg and were reversible. The protocol-defined objective response rate per Response Assessment in Neuro-Oncology criteria for LGG in patients with nonenhancing glioma was 18% (one partial response, three minor responses). The median progression-free survival was 36.8 months [95% confidence interval (CI), 11.2–40.8] for patients with nonenhancing glioma and 3.6 months (95% CI, 1.8–6.5) for patients with enhancing glioma. Exploratory evaluation of tumor volumes in patients with nonenhancing glioma showed sustained tumor shrinkage in multiple patients. Conclusions: Vorasidenib was well tolerated and showed preliminary antitumor activity in patients with recurrent or progressive nonenhancing mIDH LGG.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-21-0611

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 271

Metadata

Authors
Mellinghoff, I. K., Penas-Prado, M., Peters, K. B., Burris, H. A., Maher, E. A., Janku, F., Cote, G. M., de la Fuente, M. I., Clarke, J. L., Ellingson, B. M., Chun, S., Young, R. J., Liu, H., Choe, S., Lu, M., Le, K., Hassan, I., Steelman, L., Pandya, S. S., Cloughesy, T. F., & Wen, P. Y.
Venue
Clinical Cancer Research
Published
2021-06-02
Volume
27
Issue
16
Pages
4491-4499
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W3164133956
Cited by
271
References
32
FWCI
18.67
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-21-0611
The paper
Mellinghoff, I. K., Penas-Prado, M., Peters, K. B., Burris, H. A., Maher, E. A., Janku, F., Cote, G. M., de la Fuente, M. I., Clarke, J. L., Ellingson, B. M., Chun, S., Young, R. J., Liu, H., Choe, S., Lu, M., Le, K., Hassan, I., Steelman, L., Pandya, S. S., . . . Wen, P. Y. (2021). Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-21-0611

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.